Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials
Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrut...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2022-05-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://theijpt.org/doi/pdf/10.36401/JIPO-21-12 |
| _version_ | 1797979960635293696 |
|---|---|
| author | Thura Win Htut Myat Min Han Kyaw Zin Thein |
| author_facet | Thura Win Htut Myat Min Han Kyaw Zin Thein |
| author_sort | Thura Win Htut |
| collection | DOAJ |
| description | Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia. Patients on acalabrutinib experienced higher risk of any-grade cardiac events (risk ratio, 1.75; p = 0.01) while there was a considerable trend toward statistical significance in the risk of any-grade atrial fibrillation (risk ratio, 2.56; p = 0.05). There was no significant increase in the risk of hypertension or high-grade cardiac events or atrial fibrillation in the acalabrutinib group. |
| first_indexed | 2024-04-11T05:47:03Z |
| format | Article |
| id | doaj.art-c0220c93af63480281ddf320b0d8004f |
| institution | Directory Open Access Journal |
| issn | 2666-2345 2590-017X |
| language | English |
| last_indexed | 2024-04-11T05:47:03Z |
| publishDate | 2022-05-01 |
| publisher | Innovative Healthcare Institute |
| record_format | Article |
| series | Journal of Immunotherapy and Precision Oncology |
| spelling | doaj.art-c0220c93af63480281ddf320b0d8004f2022-12-22T04:42:12ZengInnovative Healthcare InstituteJournal of Immunotherapy and Precision Oncology2666-23452590-017X2022-05-01434710.36401/JIPO-21-12i2590-017X-5-2-43Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled TrialsThura Win Htut0Myat Min Han1Kyaw Zin Thein21 Department of Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK2 Department of Internal Medicine, Interfaith Medical Center, NY, USA3 Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USAAcalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia. Patients on acalabrutinib experienced higher risk of any-grade cardiac events (risk ratio, 1.75; p = 0.01) while there was a considerable trend toward statistical significance in the risk of any-grade atrial fibrillation (risk ratio, 2.56; p = 0.05). There was no significant increase in the risk of hypertension or high-grade cardiac events or atrial fibrillation in the acalabrutinib group.https://theijpt.org/doi/pdf/10.36401/JIPO-21-12acalabrutinibcardiac toxicitiesatrial fibrillationhypertensionchronic lymphocytic leukemia |
| spellingShingle | Thura Win Htut Myat Min Han Kyaw Zin Thein Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials Journal of Immunotherapy and Precision Oncology acalabrutinib cardiac toxicities atrial fibrillation hypertension chronic lymphocytic leukemia |
| title | Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials |
| title_full | Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials |
| title_fullStr | Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials |
| title_full_unstemmed | Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials |
| title_short | Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials |
| title_sort | acalabrutinib related cardiac toxicities in patients with chronic lymphocytic leukemia a meta analysis of randomized controlled trials |
| topic | acalabrutinib cardiac toxicities atrial fibrillation hypertension chronic lymphocytic leukemia |
| url | https://theijpt.org/doi/pdf/10.36401/JIPO-21-12 |
| work_keys_str_mv | AT thurawinhtut acalabrutinibrelatedcardiactoxicitiesinpatientswithchroniclymphocyticleukemiaametaanalysisofrandomizedcontrolledtrials AT myatminhan acalabrutinibrelatedcardiactoxicitiesinpatientswithchroniclymphocyticleukemiaametaanalysisofrandomizedcontrolledtrials AT kyawzinthein acalabrutinibrelatedcardiactoxicitiesinpatientswithchroniclymphocyticleukemiaametaanalysisofrandomizedcontrolledtrials |